Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202212018 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis New Drug Phase Ⅲ
N202212019 A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study with Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults with Myasthenia Gravis New Drug Phase Ⅲ
N202301009 A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV- 471 (PF- 07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2) New Drug Phase Ⅲ
N202301032 A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non-small Cell Lung Cancer (ARTEMIDE-01) New Drug Phase Ⅰ
N202302001 ：A Phase 3, single-arm, multicenter, multinational, open-label, oneway crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male pa rticipants aged ≥ 12 years with severe hemophilia A or B, with or without inhibitory antibodi es to factor VIII or IX New Drug Phase Ⅲ
N202302015 An Open-label, Randomized Study to Compare the Efficacy and Safety of P1101 Plus Tenofovir Alafenamide with or without Ur-sodeoxycholic Acid in Patients with Chronic Hepatitis B and Hepati-tis D Virus Co-Infection New Drug Academic Research
N202302038 A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). New Drug Phase Ⅲ
N202303029 A First-in-Human, Open-label, Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-Tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors New Drug Phase Ⅰ
N202303061 A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2) New Drug Phase Ⅱ
N202303062 A Phase 1b, Multicenter, 2-Part, Open- Label Study of Datopotamab Deruxtecan (Dato- DXd) in Combination with Immunotherapy with or without Carboplatin in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (TROPIONLung04) New Drug Phase Ⅰ
1 2 7 8 9 10 11 12 13 51 52 / 52

TOP